BASELINE HBsAg PREDICTS HBsAg LOSS AFTER 2 YEARS OF TREATMENT-FREE FOLLOW-UP IN CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON alfa-2a AND ADEFOVIR

被引：0
|
作者：
Jansen, L. [1 ]
Takkenberg, R. B. [1 ]
de Niet, A. [1 ]
Zaaijer, H. L. [1 ,2 ]
Weegink, C. J. [1 ]
Terpstra, V. [3 ]
Dijkgraaf, M. G. W. [4 ]
Molenkamp, R. [1 ]
Janssen, P. L. M. [1 ]
Koot, M. [5 ]
Rijckborst, V. [6 ]
Janssen, H. L. A. [6 ]
Beld, M. G. H. M. [1 ]
Reesink, H. W. [1 ]
机构：
[1] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands
[2] Sanquin, Blood Borne Infect, Amsterdam, Netherlands
[3] Bronovo Hosp, The Hague, Netherlands
[4] Univ Amsterdam, Acad Med Ctr, Clin Res Unit, NL-1105 AZ Amsterdam, Netherlands
[5] Sanquin, Virus Diagnost Serv, Amsterdam, Netherlands
[6] Univ Rotterdam Hosp, Erasmus MC, Rotterdam, Netherlands
来源：
JOURNAL OF HEPATOLOGY | 2013年 / 58卷
关键词：
D O I：
10.1016/S0168-8278(13)60755-2
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
753
引用
收藏
页码：S305 / S305
页数：1
相关论文
共 50 条
  • [21] Early HBeAg Loss During Peginterferon α-2b Therapy Predicts HBsAg Loss: Results of a Long-Term Follow-Up Study in Chronic Hepatitis B Patients
    Buster, Erik H. C. J.
    Flink, Hajo J.
    Simsek, Halis
    Heathcote, E. Jenny
    Sharmila, Sachithanandan
    Kitis, George E.
    Gerken, Guido
    Buti, Maria
    de Vries, Richard A.
    Verhey, Elke
    Hansen, Bettina E.
    Janssen, Harry L. A.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 (10): : 2449 - 2457
  • [22] Significant reduction of HBsAg in the sera of HBeAg-negative chronic hepatitis B patients treated with peginterferon alfa-2A alone or in combination with lamivudine
    Brunetto, Maurizia
    Bonino, Ferruccio
    Moriconi, Francesco
    Patrick, Marcellin
    George, Lau K.
    Patrizia, Farci
    Yurdaydin, Cihan
    Piratvisuth, Teerha
    Luo, Kangxian
    Wang, Yuming
    Hadziyannis, Stephanos
    Wolf, Eva
    Matei, Popescu
    HEPATOLOGY, 2006, 44 (04) : 549A - 549A
  • [23] HIGH RATES OF HEPATITIS B SURFACE ANTIGEN (HBSAG) LOSS AND SEROCONVERSION FOLLOWING A PROLONGED COURSE OF TREATMENT WITH PEGINTERFERON ALFA-2A
    Li, Ming-hui
    Xie, Yao
    Lu, Yao
    Qiu, Guo-hua
    Liu, Feng
    Li, Xing-hong
    Song, Shu-jing
    Guan, Xiao-ping
    Cheng, Jun
    Xu, Dao-Zhen
    HEPATOLOGY, 2010, 52 (04) : 538A - 538A
  • [24] Sustained HBeAg and HBsAg loss after longterm follow-up of HBeAg positive patients treated with peginterferon alpha-2B
    Buster, Erik H.
    Flink, Hajo J.
    Cakaloglu, Yilmaz
    Simon, Christopher
    Trojan, Joerg
    Tabak, Fehmi
    So, Thomas M.
    Feinman, Victor S.
    Mach, Tomasz
    Akarca, Ulus
    Tielemans, Wanda C.
    van Vuuren, Hanneke J.
    Hansen, Bettina E.
    Janssen, Harry L.
    HEPATOLOGY, 2007, 46 (04) : 667A - 667A
  • [25] HBsAg loss in patients treated with peginterferon alfa-2a and adefovir is associated with SLC16A9 gene variation and lower plasma carnitine levels
    Jansen, Louis
    de Niet, Annikki
    Stelma, Femke
    van Iperen, Erik P. A.
    van Dort, Karel A.
    Plat-Sinnige, Marjan J. Tempelmans
    Takkenberg, R. Bart
    Chin, Daniel J.
    Zwinderman, A. H.
    Lopatin, Uri
    Kootstra, Neeltje A.
    Reesink, Hendrik W.
    JOURNAL OF HEPATOLOGY, 2014, 61 (04) : 730 - 737
  • [26] HBSAG CLEARANCE CONTINUES TO INCREASE POST-TREATMENT IN PATIENTS WITH HCV/HBV COINFECTION TREATED WITH PEGINTERFERON ALFA-2A PLUS RIBAVIRIN: 1.5 YEAR FOLLOW-UP
    Liu, Chun-Jen
    Chuang, Wan-Long
    Lee, Chuan-Mo
    Yu, Ming-Lung
    Lu, Sheng-Nan
    Dai, Chia-Yen
    Huang, Jee-Fu
    Hu, Tsung-Hui
    Chen, Chien-Hung
    Hung, Chao-Hung
    Wang, J. H.
    Wu, Shun-Sheng
    Liao, L. Y.
    Kuo, H. T.
    Chao, You-Chen
    Tung, S. Y.
    Yang, Sien-Sing
    Su, W. W.
    Lin, Chih-Lin
    Kao, Jia-Horng
    Liu, Chen-Hua
    Chen, Pei-Jer
    Chen, Ding-Shinn
    HEPATOLOGY, 2009, 50 (04) : 503A - 504A
  • [27] HIGH LEVELS OF HBSAG AND HBV DNA DURING TREATMENT PREDICT FAILURE FOR HBEAG SEROCONVERSION IN HBEAG POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON ALFA-2A (PEGASYS®) AND ADEFOVIR (HEPSERA); AN INTERIM ANALYSIS
    Takkenberg, Bart
    Zaaijer, Hans L.
    de Niet, Annikki
    Weegink, Christine J.
    Terpstra, Valeska
    Koot, Maarten
    Dijkgraaf, Marcel
    Jansen, Peter L.
    Janssen, Harry L.
    Beld, Marcel
    Reesink, Hendrik W.
    HEPATOLOGY, 2009, 50 (04) : 541A - 541A
  • [28] Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss - results of a long-term follow-up study in chronic hepatitis B
    Buster, E. H. C. J.
    Flink, H. J.
    Simsek, H.
    Heathcote, E. J.
    Sharmila, S.
    Kitis, G. E.
    Gerken, G.
    Buti, M.
    de Vries, R. A.
    Verhey, E.
    Hansen, B. E.
    Janssen, H. L. A.
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2009, 21 (03) : A52 - A53
  • [29] EARLY HBEAG LOSS DURING PEGINTERFERON ALPHA-2B THERAPY PREDICTS HBSAG LOSS - RESULTS OF A LONG-TERM FOLLOW-UP STUDY IN CHRONIC HEPATITIS B
    Buster, Erik H.
    Flink, Hajo J.
    Simsek, Halis
    Heathcote, E. Jenny
    Sharmila, Sachithanandan
    Kitiss, George E.
    Gerken, Guido
    Buti, Maria
    de Vries, Richard A.
    Verhey, Elke
    Hansen, Bettina E.
    Janssen, Harry L.
    HEPATOLOGY, 2008, 48 (04) : 723A - 723A
  • [30] Long-term follow-up of HBsAg clearance in patients with HBeAg-negative CHB treated with Peginterferon alfa-2a: Increase in HBsAg, clearance rate from 3% 6 months post-treatment to 8% after 3 years
    Marcellin, Patrick
    Brunetto, Maurizia
    Bonino, Ferruccio
    Lau, George K.
    Farci, Patrizia
    Yurdaydin, Cihan
    Piratvisuth, Teerha
    Luo, K.
    Wang, Y.
    Hadziyannis, Stephanos J.
    Wolf, Eva
    Popescu, Matei
    HEPATOLOGY, 2007, 46 (04) : 673A - 674A
12345